Trial Profile

Evaluation of an eXtended and proacTive Dosing regimEn in Treatment-Naïve Patients With Wet Age-related Macular Degeneration (wAMD)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 26 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aflibercept (Primary)
Indications Wet age-related macular degeneration
Focus Therapeutic Use
Acronyms XTEND
Sponsors Bayer

Most Recent Events

20 Jun 2025 According to data from this study ,data from this study presented at at the annual International Society on Thrombosis and Haemostasis (ISTH) Congress in Washington (21-25 June).
26 Oct 2023 Status changed from active, no longer recruiting to completed.
21 Jul 2023 Planned primary completion date changed from 14 Aug 2023 to 11 Aug 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com